Abstract Number: 2361 • ACR Convergence 2025
Secondary Outcomes from a Series of N-of-1 NSAID Trials in Axial Spondyloarthritis: Functional, Quality-of-Life, and Safety Results from a Bayesian Analysis
Background/Purpose: We previously reported primary outcomes from a Bayesian series of N-of-1 trials comparing celecoxib, meloxicam, and naproxen in axial spondyloarthritis (axSpA), demonstrating improved ASDAS…Abstract Number: 2103 • ACR Convergence 2025
PCRX-201 High-Capacity Adenovirus Serotype 5 Gene Therapy Demonstrates Sustained Clinical Efficacy and Safety in Patients With Knee Osteoarthritis
Background/Purpose: Knee OA is a common disease affecting ~15 million people in the United States. There is an urgent unmet need for additional OA treatments…Abstract Number: 1925 • ACR Convergence 2025
Associations between Representation and Quality in Clinical Trials for Systemic Lupus Erythematosus
Background/Purpose: Drug development in SLE is informed by US Food and Drug Administration recommendations for study design, enrollment, and efficacy endpoints. However, persistent challenges to…Abstract Number: 1519 • ACR Convergence 2025
Post-hoc Analysis of Sustained Response Over Time in Systemic Lupus Erythematosus Patients Treated with Cenerimod in CARE (Phase 2 B) Study
Background/Purpose: Cenerimod is a highly selective S1P1 receptor modulator which is undergoing trials for potential therapeutic benefits in autoimmune disease, including Systemic Lupus Erythematous (SLE).…Abstract Number: 1356 • ACR Convergence 2025
Use of (MSB11456), the first tocilizumab biosimilar approved for rheumatoid arthritis: 6-month data from an international observational study
Background/Purpose: Although most healthcare professionals are convinced of the quality, safety, and favorable economic impact of biosimilars, their routine use is not yet widespread. MSB11456…Abstract Number: 0663 • ACR Convergence 2025
iPSC-Derived Off-the-Shelf anti-CD19 CAR T cells Deliver Improved Clinical Outcomes in Lupus with Reduced or No Conditioning Chemotherapy
Background/Purpose: Anti-CD19 chimeric antigen receptor (CAR) T cell therapy shows promise in autoimmune disease. However, autologous CAR T-cell therapy is limited by prolonged pre- and…Abstract Number: 0891 • ACR Convergence 2025
MEthotrexate versus TOcilizumab for treatment of Giant cell Arteritis (METOGiA trial): a multicenter, randomized, controlled trial.
Background/Purpose: This trial aimed to compare the efficacy and safety of methotrexate (MTX) vs. tocilizumab (TCZ), in combination with glucocorticoid (GC), in patients with giant…Abstract Number: 0501 • ACR Convergence 2025
Phase 1b Study of SBT777101, an Engineered CAR-T-Regulatory Cell Product, in Patients With Rheumatoid Arthritis: Interim Demographics and Safety
Background/Purpose: Regulatory T cells (Tregs) modulate inflammation, maintain self-tolerance, and promote tissue repair, and thus hold promise as a versatile therapeutic tool. Autologous polyclonal Tregs…Abstract Number: 0310 • ACR Convergence 2025
Evaluate Safety, Tolerability, and Pharmacodynamics of a Single Intra-Articular Injection of GNSC-001 Gene Therapy in Subjects with Knee Osteoarthritis: 12-month Results from DONATELLO
Background/Purpose: IL-1 contributes significantly to osteoarthritis (OA) pathology, driving inflammation and cartilage degradation. Prior therapies targeting IL-1 have shown limited success due to inadequate drug…Abstract Number: 2576 • ACR Convergence 2025
Methotrexate Treatment of Arthritis Caused by Chikungunya Virus (MARCH) Study: Anti-inflammatory cytokine signals related to decreased arthritis disease activity over time
Background/Purpose: The MARCH study evaluates the efficacy of methotrexate monotherapy in patients with chikungunya-associated arthritis and aims to elucidate its pathologic mechanism via cytokine analysis.…Abstract Number: 2362 • ACR Convergence 2025
Long-Term Efficacy and Safety of Risankizumab for csDMARD-IR Patients With Active Psoriatic Arthritis: 244-Week Results From the KEEPsAKE 1 Trial
Background/Purpose: Risankizumab (RZB), an anti-interleukin 23p19 monoclonal antibody, is approved for the treatment of adults with active PsA. We report the efficacy and safety of…Abstract Number: 2101 • ACR Convergence 2025
LEVI-04, a Novel Neurotrophin-3 Inhibitor, Demonstrates Clinically Meaningful Improvements in Pain and Physical Function across a Range of OA Outcomes, Including the Staircase-Evoked Pain Procedure (StEPP)
Background/Purpose: When evaluating new osteoarthritis (OA) therapies, we need to understand their clinical meaningfulness. LEVI-04, a first-in-class p75 neurotrophin receptor-Fc fusion protein that primarily inhibits…Abstract Number: 1769 • ACR Convergence 2025
Classification of Relapses of Eosinophilic Granulomatosis with Polyangiitis After Two-Years of Treatment with Anti-Interleukin-5/Receptor Therapy
Background/Purpose: Results from the ongoing open-label extension (OLE) of the MANDARA trial (NCT04157348) have demonstrated the efficacy of two years of anti-interleukin-5/receptor (anti-IL-5/R) therapies in…Abstract Number: 1466 • ACR Convergence 2025
Impact of Bimekizumab on Spinal MRI Inflammation and Structural Lesions in Patients with Radiographic Axial Spondyloarthritis: 2-Year CANDEN Scoring Results from a Phase 3 Study and Its Open-Label Extension
Background/Purpose: Spinal inflammation and structural progression are key features of radiographic axial spondyloarthritis (r-axSpA).1 Canada-Denmark (CANDEN) scoring enables anatomical-based assessments of MRI inflammatory and structural…Abstract Number: 1353 • ACR Convergence 2025
Phase 3 Study of the Efficacy, Safety and Immunogenicity of the Proposed Tocilizumab Biosimilar RGB-19, Intravenously Administered to Participants With Active Rheumatoid Arthritis: 52-Week Data
Background/Purpose: RGB-19 is a proposed biosimilar to tocilizumab, a monoclonal antibody that competitively inhibits the binding of interleukin-6 (IL-6) to its receptor. Results of a…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 55
- Next Page »
